Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
The drug's active form, ALS-8112 -TP, disables RSV polymerase by causing RNA synthesis to terminate at the 5'-triphosphate [2]. After entering different kinds of respiratory tract epithelial cells, ALS-008112 is phosphorylated to produce intracellular nucleoside triphosphates, which have a half-life of roughly 29. RSV replication is similarly inhibited by hourly nucleoside triphosphates via chain termination [3]. With an IC50 of 0.020 ± 0.008 μM, ALS-8112 is an external RSV replicating ubiquitin ALS-8112-TP that proportionally suppresses the RSV–RNP complex's RNA regulatory action [4].
|
---|---|
References |
|
Molecular Formula |
C10H13CLFN3O4
|
---|---|
Molecular Weight |
293.6793
|
Exact Mass |
293.057
|
CAS # |
1445379-92-9
|
Related CAS # |
Lumicitabine;1445385-02-3
|
PubChem CID |
71621663
|
Appearance |
White to off-white solid powder
|
Density |
1.8±0.1 g/cm3
|
Boiling Point |
532.8±60.0 °C at 760 mmHg
|
Flash Point |
276.0±32.9 °C
|
Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
Index of Refraction |
1.668
|
LogP |
-0.42
|
Hydrogen Bond Donor Count |
3
|
Hydrogen Bond Acceptor Count |
5
|
Rotatable Bond Count |
3
|
Heavy Atom Count |
19
|
Complexity |
447
|
Defined Atom Stereocenter Count |
4
|
SMILES |
C1=CN(C(=O)N=C1N)[C@H]2[C@@H]([C@@H]([C@](O2)(CO)CCl)O)F
|
InChi Key |
AWSRKKBIPSQHOJ-IBCQBUCCSA-N
|
InChi Code |
InChI=1S/C10H13ClFN3O4/c11-3-10(4-16)7(17)6(12)8(19-10)15-2-1-5(13)14-9(15)18/h1-2,6-8,16-17H,3-4H2,(H2,13,14,18)/t6-,7+,8-,10-/m1/s1
|
Chemical Name |
4-amino-1-[(2R,3R,4R,5R)-5-(chloromethyl)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 47 mg/mL (~160.04 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.51 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.51 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.4051 mL | 17.0253 mL | 34.0507 mL | |
5 mM | 0.6810 mL | 3.4051 mL | 6.8101 mL | |
10 mM | 0.3405 mL | 1.7025 mL | 3.4051 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.